New alarm over China controlling drug supply chains
Summary
A congressional biotechnology commission warned that growing partnerships between U.S. drugmakers and Chinese biotech firms could increase U.S. reliance on China for pharmaceutical innovation and supplies. The Trump administration has proposed screening or prohibiting some deals with Chinese life sciences companies.Key Facts
- The commission analyzed 57 licensing deals involving Western drugmakers and Chinese firms from early 2023 through October 2026.
- The commission said deals are happening earlier in drug development, often using preclinical data and making payments earlier in research and development.
- Drugmakers including AstraZeneca, Bristol Myers Squibb and Pfizer have pursued deals with Chinese biotech firms.
- Chinese firms can gain funding and expertise in developing and commercializing treatments through these partnerships.
- The commission warned that royalties and joint-venture equity could help fund further Chinese research and infrastructure.
- China proposed new export restrictions last month that include some cell and gene therapy technologies.
- The Trump administration proposed screening or prohibiting certain deals with Chinese life sciences companies over national security and supply-chain concerns.
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.